Dr. Adam Greenbaum and Dr. Serge Korjian Discuss: One-year Results Of The Clasp TR Study: Transcatheter Treatment Of Tricuspid Regurgitation April 4, 2022 Disclosures: TBA
Dr. Maura Marcucci and Dr. Yazan Daaboul Discuss: POISE-3: The Effects Of A Hypotension-avoidance Strategy Versus A Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery April 4, 2022 Disclosures: TBA
Dr. Daniel Sessler and Dr. C. Michael Gibson Discuss: The PROTECT Trial: Very Mild Perioperative Hypothermia Versus Aggressive Warming And Myocardial Injury After Non-cardiac Surgery April 4, 2022 Disclosures: TBA
Dr. Ajay Kirtane and Dr. C. Michael Gibson Discuss: ACC 2022 Wrap-Up – Sunday, April 3 April 3, 2022 Disclosures: TBA
Dr. Jose Luis Leiva Pons and Dr. Cecilia Bahit Discuss: ACC 2022 Wrap-Up in Spanish April 3, 2022 Disclosures: TBA
Dr. Steven Nissen and Dr. C. Michael Gibson Discuss: VALOR-HCM: Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy April 3, 2022 Disclosures: TBA
Dr. Yutao Guo and Dr. Yazan Daaboul Discuss: A Report From The mAFA-II Trial Long-term Extension Cohort: Consumer-led Screening For Atrial Fibrillation April 3, 2022 Disclosures: TBA
Dr. Manesh Patel and Dr. C. Michael Gibson Discuss: PACIFIC AF: Multicenter, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study Comparing The Safety Of The Oral FXIa Inhibitor Asundexian With Apixaban In Patients With Atrial Fibrillation April 3, 2022 Disclosures: TBA
Dr. Javed Butler and Dr. C. Michael Gibson Discuss: DIAMOND Trial: Patiromer For The Management Of Hyperkalemia In Subjects Receiving Renin-angiotensin-aldosterone System Inhibitor Medications For Heart Failure With Reduced Ejection Fraction April 3, 2022 Disclosures: TBA
Dr. Mark Loeb and Dr. C. Michael Gibson Discuss: IVVE: Randomized Controlled Trial Of Influenza Vaccine In Patients With Heart Failure To Reduce Adverse Vascular Events April 3, 2022 Disclosures: TBA
